Skip to main content
×
×
Home

Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies

  • Borwin Bandelow (a1), Anne Sagebiel (a1), Michael Belz (a1), Yvonne Görlich (a1), Sophie Michaelis (a1) and Dirk Wedekind (a1)...
Abstract
Background

It is a widespread opinion that after treatment with psychotherapy, patients with anxiety disorders maintain their gains beyond the active treatment period, whereas patients treated with medication soon experience a relapse after treatment termination.

Aims

We aimed to provide evidence on whether enduring effects of psychotherapy differ from control groups.

Method

We searched 93 randomised controlled studies with 152 study arms of psychological treatment (cognitive–behavioural therapy or other psychotherapies) for panic disorder, generalised anxiety disorder and social anxiety disorder that included follow-up assessments. In a meta-analysis, pre-post effect sizes for end-point and all follow-up periods were calculated and compared with control groups (medication: n = 16 study arms; pill and psychological placebo groups: n = 17 study arms).

Results

Gains with psychotherapy were maintained for up to 24 months. For cognitive–behavioural therapy, we observed a significant improvement over time. However, patients in the medication group remained stable during the treatment-free period, with no significant difference when compared with psychotherapy. Patients in the placebo group did not deteriorate during follow-up, but showed significantly worse outcomes than patients in cognitive–behavioural therapy.

Conclusions

Not only psychotherapy, but also medications and, to a lesser extent, placebo conditions have enduring effects. Long-lasting treatment effects observed in the follow-up period may be superimposed by effects of spontaneous remission or regression to the mean.

Declaration of interest

In the past 12 months and in the near future, Dr Bandelow has been/will be on the speakers/advisory board for Hexal, Mundipharma, Lilly, Lundbeck, Pfizer and Servier. Dr Wedekind was on the speakers' board of AstraZeneca, Essex Pharma, Lundbeck and Servier. All other authors have nothing to declare.

Copyright
Corresponding author
Correspondence: Dr Borwin Bandelow, Department of Psychiatry and Psychotherapy, University of Göttingen, von-Siebold-Straβe 5, D-37075 Göttingen, Germany. Email: bbandel@gwdg.de
References
Hide All
1Bandelow, B, Zohar, J, Hollander, E, Kasper, S, Moller, HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9(4): 248312.
2Baldwin, DS, Anderson, IM, Nutt, DJ, Allgulander, C, Bandelow, B, den Boer, JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28(5): 403–39.
3National Institute for Health and Care Excellence (NICE). Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. The British Psychological Society and The Royal College of Psychiatrists, 2011.
4Bandelow, B, Reitt, M, Rover, C, Michaelis, S, Gorlich, Y, Wedekind, D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30(4): 183–92.
5National Institute for Health and Care Excellence (NICE). Anxiety (amended): Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. NICE, 2007.
6National Institute for Health and Care Excellence (NICE). Social Anxiety Disorder: Recognition, Assessment and Treatment (Full Guideline). The British Psychological Society and The Royal College of Psychiatrists, 2013.
7Durham, RC, Chambers, JA, Power, KG, Sharp, DM, Macdonald, RR, Major, KA, et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technol Assess 2005; 9(42): 1174.
8Donovan, MR, Glue, P, Kolluri, S, Emir, B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a meta-analysis. J Affect Disord 2010; 123(1–3): 916.
9Marks, IM, Swinson, RP, Basoglu, M, Kuch, K, Noshirvani, H, O'Sullivan, G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993; 162: 776–87.
10Loerch, B, Graf-Morgenstern, M, Hautzinger, M, Schlegel, S, Hain, C, Sandmann, J, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999; 174: 205–12.
11Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283(19): 2529–36.
12Cohen, SD, Monteiro, W, Marks, IM. Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry 1984; 144(3): 276–81.
13Mavissakalian, M, Michelson, L, Dealy, RS. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 1983; 143: 348–55.
14Clark, DM, Ehlers, A, McManus, F, Hackmann, A, Fennell, M, Campbell, H, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71(6): 1058–67.
15Nordahl, HM, Vogel, PA, Morken, G, Stiles, TC, Sandvik, P, Wells, A. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychother Psychosom 2016; 85(6): 346–56.
16Liebowitz, MR, Heimberg, RG, Schneier, FR, Hope, DA, Davies, S, Holt, CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999; 10(3): 8998.
17Haug, TT, Blomhoff, S, Hellstrom, K, Holme, I, Humble, M, Madsbu, HP, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003; 182: 312–8.
18Patterson, B, Boyle, MH, Kivlenieks, M, Van Ameringen, M. The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res 2016; 83: 112–20.
19Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: A guideline developer's handbook. SIGN, 2015 (www.sign.ac.uk/assets/sign50_2015.pdf).
20Leichsenring, F, Salzer, S, Beutel, ME, Herpertz, S, Hiller, W, Hoyer, J, et al. Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder. Am J Psychiatry 2014; 171: 1074–82.
21Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50–5.
22Liebowitz, MR. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141–73.
23Dunlap, WP, Cortina, JM, Vaslow, JB, Burke, MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods 1996; 1(2): 170–7.
24Borenstein, M, Hedges, L, Higgins, J, Rothstein, H. Introduction to Meta-Analysis. Wiley, 2009.
25Little, RJ, D'Agostino, R, Cohen, ML, Dickersin, K, Emerson, SS, Farrar, JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367(14): 1355–60.
26Ioannidis, JP, Patsopoulos, NA, Evangelou, E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007; 335(7626): 914–6.
27Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557–60.
28Moher, D, Altman, DG, Liberati, A, Tetzlaff, J. PRISMA statement. Epidemiology 2011; 22(1): 128.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 13
Total number of PDF views: 89 *
Loading metrics...

Abstract views

Total abstract views: 782 *
Loading metrics...

* Views captured on Cambridge Core between 30th April 2018 - 24th May 2018. This data will be updated every 24 hours.

Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies

  • Borwin Bandelow (a1), Anne Sagebiel (a1), Michael Belz (a1), Yvonne Görlich (a1), Sophie Michaelis (a1) and Dirk Wedekind (a1)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *